Impact of prior cerebrovascular disease and glucose status on incident cerebrovascular disease in Japanese

[1]  H. Kamel,et al.  2021 Guideline for the Prevention of Stroke in Patients With Stroke and Transient Ischemic Attack: A Guideline From the American Heart Association/American Stroke Association. , 2021, Stroke.

[2]  K. Akazawa,et al.  Accuracy of Japanese claims data in identifying diabetes‐related complications , 2021, Pharmacoepidemiology and drug safety.

[3]  Xin Yu,et al.  Research progress on the role of gal-3 in cardio/cerebrovascular diseases. , 2021, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[4]  ESC / EAS Guidelines for the Treatment of Dyslipidemias: Lipid Modification to Reduce Cardiovascular Risk , 2020, Digital Doctor.

[5]  E. Vicaut,et al.  Five-Year Prognosis After TIA or Minor Ischemic Stroke in Asian and Non-Asian Populations , 2020, Neurology.

[6]  Ji-zong Zhao,et al.  Elevated levels of adiponectin associated with major adverse cardiovascular and cerebrovascular events and mortality risk in ischemic stroke , 2020, Cardiovascular Diabetology.

[7]  Jason H. Y. Wu,et al.  Association between prediabetes and risk of all cause mortality and cardiovascular disease: updated meta-analysis , 2020, BMJ.

[8]  Han-Yeong Jeong,et al.  High triglyceride-glucose index is associated with subclinical cerebral small vessel disease in a healthy population: a cross-sectional study , 2020, Cardiovascular Diabetology.

[9]  F. Azizi,et al.  Change in glucose intolerance status and risk of incident cardiovascular disease: Tehran Lipid and Glucose Study , 2020, Cardiovascular Diabetology.

[10]  K. Fujihara,et al.  Relationship between Number of Multiple Risk Factors and Coronary Artery Disease Risk With and Without Diabetes Mellitus. , 2019, The Journal of clinical endocrinology and metabolism.

[11]  K. Shimada,et al.  Effect of Standard vs Intensive Blood Pressure Control on the Risk of Recurrent Stroke: A Randomized Clinical Trial and Meta-analysis. , 2019, JAMA neurology.

[12]  G. Hindricks,et al.  2019 ESC/EAS guidelines for the management of dyslipidaemias: Lipid modification to reduce cardiovascular risk. , 2019, Atherosclerosis.

[13]  K. Fujihara,et al.  Risk of coronary artery disease according to glucose abnormality status and prior coronary artery disease in Japanese men. , 2019, Metabolism: clinical and experimental.

[14]  Yafeng Wang,et al.  Sex differences in the association between diabetes and risk of cardiovascular disease, cancer, and all-cause and cause-specific mortality: a systematic review and meta-analysis of 5,162,654 participants , 2019, BMC Medicine.

[15]  Daniel E Forman,et al.  2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. , 2019, Journal of the American College of Cardiology.

[16]  O. Pedersen,et al.  Beneficial impact of intensified multifactorial intervention on risk of stroke: outcome of 21 years of follow-up in the randomised Steno-2 Study , 2019, Diabetologia.

[17]  Fares Alahdab,et al.  Global, regional, and national burden of stroke, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016 , 2019, The Lancet Neurology.

[18]  F. Azizi,et al.  Sex-specific clinical outcomes of impaired glucose status: A long follow-up from the Tehran Lipid and Glucose Study , 2019, European journal of preventive cardiology.

[19]  S. Kihara,et al.  Japan Atherosclerosis Society (JAS) Guidelines for Prevention of Atherosclerotic Cardiovascular Diseases 2017 , 2018, Journal of atherosclerosis and thrombosis.

[20]  S. Rajsic,et al.  Economic burden of stroke: a systematic review on post-stroke care , 2018, The European Journal of Health Economics.

[21]  V. Thijs,et al.  Relationship Between Glycated Hemoglobin and Stroke Risk: A Systematic Review and Meta‐Analysis , 2018, Journal of the American Heart Association.

[22]  Y. Ohashi,et al.  Effect of an intensified multifactorial intervention on cardiovascular outcomes and mortality in type 2 diabetes (J-DOIT3): an open-label, randomised controlled trial. , 2017, The lancet. Diabetes & endocrinology.

[23]  S. Bangalore,et al.  Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. , 2017, The American journal of medicine.

[24]  K. Fujihara,et al.  Impact of glucose tolerance status on the development of coronary artery disease among working-age men. , 2017, Diabetes & metabolism.

[25]  Yuli Huang,et al.  Association between prediabetes and risk of cardiovascular disease and all cause mortality: systematic review and meta-analysis , 2016, British Medical Journal.

[26]  S. Yusuf,et al.  Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study , 2016, The Lancet.

[27]  Shanzhu Zhu,et al.  Diabetes is an Independent Risk Factor for Stroke Recurrence in Stroke Patients: A Meta-analysis. , 2015, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[28]  H. Nathoe,et al.  The Relation Between HbA1c and Cardiovascular Events in Patients With Type 2 Diabetes With and Without Vascular Disease , 2015, Diabetes Care.

[29]  Jennette P. Moreno,et al.  Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes , 2014, Current Atherosclerosis Reports.

[30]  E. Di Angelantonio,et al.  Types of Stroke Recurrence in Patients with Ischemic Stroke: A Substudy from the PRoFESS Trial , 2014, International journal of stroke : official journal of the International Stroke Society.

[31]  A. Tamakoshi,et al.  Three percent weight reduction is the minimum requirement to improve health hazards in obese and overweight people in Japan. , 2014, Obesity research & clinical practice.

[32]  Kuo-Hsuan Chang,et al.  Effect of pre-diabetes on future risk of stroke: meta-analysis , 2012, BMJ : British Medical Journal.

[33]  Kortaro Tanaka,et al.  One-year atherothrombotic vascular events rates in outpatients with recent non-cardioembolic ischemic stroke: the EVEREST (Effective Vascular Event REduction after STroke) registry. , 2012, Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association.

[34]  I. D. de Boer,et al.  Fasting and Post-Glucose Load Measures of Insulin Resistance and Risk of Ischemic Stroke in Older Adults , 2011, Stroke.

[35]  Makoto Watanabe,et al.  Lifestyle modification and prevention of type 2 diabetes in overweight Japanese with impaired fasting glucose levels: a randomized controlled trial. , 2011, Archives of internal medicine.

[36]  P. Heuschmann,et al.  Risk and Cumulative Risk of Stroke Recurrence: A Systematic Review and Meta-Analysis , 2011, Stroke.

[37]  M. Fornage,et al.  Guidelines for the Primary Prevention of Stroke: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2011, Stroke.

[38]  J. Danesh,et al.  Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies , 2010, The Lancet.

[39]  David M Nathan,et al.  10-year follow-up of diabetes incidence and weight loss in the Diabetes Prevention Program Outcomes Study. , 2009, Lancet.

[40]  Takeo Kato,et al.  Impaired glucose tolerance is a risk factor for stroke in a Japanese sample--the Funagata study. , 2008, Metabolism: clinical and experimental.

[41]  A. Avogaro,et al.  Incidence and Risk Factors for Stroke in Type 2 Diabetic Patients: The DAI Study , 2007, Stroke.

[42]  S. Ibayashi,et al.  Ten year recurrence after first ever stroke in a Japanese community: the Hisayama study , 2005, Journal of Neurology, Neurosurgery & Psychiatry.

[43]  O. Pedersen,et al.  Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. , 2003, The New England journal of medicine.

[44]  V. Tikhonoff,et al.  Predictors of stroke mortality in elderly people from the general population , 2001, European Journal of Epidemiology.

[45]  Philip D. Harvey,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38 , 1998, BMJ.

[46]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[47]  R. Holman,et al.  Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. , 1998 .

[48]  Joël Ménard,et al.  Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial , 1998, The Lancet.

[49]  T. Olsen,et al.  Outcome and time course of recovery in stroke. Part I: Outcome. The Copenhagen Stroke Study. , 1995, Archives of physical medicine and rehabilitation.

[50]  G. Bray,et al.  Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes. , 2013, The New England journal of medicine.

[51]  [Japan Atherosclerosis Society (JAS) guidelines for prevention of atherosclerotic cardiovascular diseases]. , 2007, Journal of atherosclerosis and thrombosis.

[52]  Teven,et al.  MORTALITY FROM CORONARY HEART DISEASE IN SUBJECTS WITH TYPE 2 DIABETES AND IN NONDIABETIC SUBJECTS WITH AND WITHOUT PRIOR MYOCARDIAL INFARCTION , 2000 .